Advertisement

Leukemia Stem Cells

  • Markus Müschen
Chapter

Abstract

Normal hematopoiesis develops hierarchically from a hematopoietic stem cell, which is defined by both extensive self-renewal capacity and multi-lineage potential, i.e. the ability to give rise to fully differentiated cells of all hematopoietic lineages. Since leukemia can be considered as malignant hematopoiesis, the existence of a developmental hierarchy in leukemia with a malignant stem cell at its apex was postulated almost three decades ago. Recent data questioned the presence of a unique leukemia stem cell population in some subtypes of leukemia. In other leukemia subtypes, however, leukemia stem cell populations have been extensively characterized with respect to their self-renewal capacity, multilineage potential, their phenotype and the signaling pathways that are required for their maintenance. Importantly, recent data show that leukemia stem cells are not only required for initiation of leukemia at its onset. They also represent the rare leukemia cell population that gives rise to relapse and drug-resistance of the disease in patients. Here, current data on the cellular origin, phenotype and central signaling pathways of self-renewal in acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) subtypes of leukemia are being reviewed.

Keywords

Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML) Chronic myeloid leukemia (CML) Leukemia stem cell (LSC) SCID-repopulating cell (SRC) SCID leukemia-initiating cell (SL-IC) 

References

  1. 1.
    Fialkow P et al. (1981) Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood 57:1068–1073.PubMedGoogle Scholar
  2. 2.
    Huntly BJ, Gilliland DG (2005) Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5:311–321.PubMedCrossRefGoogle Scholar
  3. 3.
    Barnes DJ, Melo JV (2006) Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 5:2862–2866.PubMedCrossRefGoogle Scholar
  4. 4.
    Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737.PubMedCrossRefGoogle Scholar
  5. 5.
    Lapidot T, Sirard C, Vormoor J et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645–648.PubMedCrossRefGoogle Scholar
  6. 6.
    Passegue E, Jamieson CH, Ailles LE et al. (2003) Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci USA 100:11842–11849.PubMedCrossRefGoogle Scholar
  7. 7.
    Krivtsov AV, Twomey D, Feng Z et al. (2006) Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442:818–822.PubMedCrossRefGoogle Scholar
  8. 8.
    Steidl U, Rosenbauer F, Verhaak RG et al. (2006) Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet 38:1269–1277.PubMedCrossRefGoogle Scholar
  9. 9.
    Hope KJ, Jin L, Dick JE et al. (2004) Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 5:738–743.PubMedCrossRefGoogle Scholar
  10. 10.
    Cozzio A, Passegue E, Ayton PM et al. (2003) Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 17:3029–3035.PubMedCrossRefGoogle Scholar
  11. 11.
    Huntly BJ, Shigematsu H, Deguchi K et al. (2004) MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6:587–596.PubMedCrossRefGoogle Scholar
  12. 12.
    Blair A, Hogge DE, Ailles LE, et al. (1997) Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 89:3104–3112.PubMedGoogle Scholar
  13. 13.
    Jordan CT et al. (2000) The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14:1777–1784.PubMedCrossRefGoogle Scholar
  14. 14.
    Anand S, Chan WI, Kvinlaug BT et al. (2007) Targeting critical pathways in leukemia stem cells. Hematology Education the education program of the annual congress of the European Hematology Association 2007. 1:175–182.Google Scholar
  15. 15.
    Hosen N, Park CY, Tatsumi N, et al. (2007) CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA. 104:11008–11013.PubMedCrossRefGoogle Scholar
  16. 16.
    van Rhenen A, van Dongen GA, Kelder A, et al. (2007) The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110:2659–2666.PubMedCrossRefGoogle Scholar
  17. 17.
    Jamieson CH, Ailles LE, Dylla SJ et al. (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351:657–667.PubMedCrossRefGoogle Scholar
  18. 18.
    Graham SM, Jorgensen HG, Allan E et al. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319–325.PubMedCrossRefGoogle Scholar
  19. 19.
    Modi H, McDonald T, Chu S et al. (2007) Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood 109:5411–5421.PubMedCrossRefGoogle Scholar
  20. 20.
    Zhao C, Blum J, Chen A et al. (2007) Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12:528–541.PubMedCrossRefGoogle Scholar
  21. 21.
    Zhao C, Chen A, Jamieson CH et al. (2009) Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458: 776–779PubMedCrossRefGoogle Scholar
  22. 22.
    Cox CV, Evely RS, Oakhill A et al. (2004) Characterization of acute lymphoblastic leukemia progenitor cells. Blood 104:2919–2925.PubMedCrossRefGoogle Scholar
  23. 23.
    Hotfilder M, Röttgers S, Rosemann A et al. (2005) Leukemic stem cells in childhood high-risk ALL/t(922) and t(411) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Res 65:1442–1449.PubMedCrossRefGoogle Scholar
  24. 24.
    Hong D, Gupta R, Ancliff P et al. (2008) Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319:336–339.PubMedCrossRefGoogle Scholar
  25. 25.
    Kelly PN, Dakic A, Adams JM et al. (2007) Tumor growth need not be driven by rare cancer stem cells. Science 317:337.PubMedCrossRefGoogle Scholar
  26. 26.
    Scharenberg C, Harkey M, Torok-Storb B (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507–512.PubMedCrossRefGoogle Scholar
  27. 27.
    Dean M, Fojo T, Bates S (2005) Tumor stem cells and drug resistance. Nat Rev Cancer 5:275–284.PubMedCrossRefGoogle Scholar
  28. 28.
    Guzman ML, Swiderski CF, Howard DS (2002) Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 99:16220–16225.PubMedCrossRefGoogle Scholar
  29. 29.
    Guzman ML, Rossi RM, Karnischky L et al. (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105:4163–4169.PubMedCrossRefGoogle Scholar
  30. 30.
    Yalcintepe L, Frankel AE, Hogge DE (2006) Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood 108:3530–3537.PubMedCrossRefGoogle Scholar
  31. 31.
    Pui CH, Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166–178.PubMedCrossRefGoogle Scholar
  32. 32.
    Sadowitz PD, Smith SD, Shuster J et al. (1993) Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 81:602–609.PubMedGoogle Scholar
  33. 33.
    Gaynon PS (2005) Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 131:579–587.PubMedCrossRefGoogle Scholar
  34. 34.
    Kong Y, Yoshida S, Saito Y et al. (2008) CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 22:1207–1213.PubMedCrossRefGoogle Scholar
  35. 35.
    Thomas M, Gessner A, Vornlocher HP et al. (2005) Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(411)-positive human leukemic cells. Blood 106:3559–3566.PubMedCrossRefGoogle Scholar
  36. 36.
    Laurent E, Talpaz M, Kantarjian H et al. (2001) The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res 61:2343–2355.PubMedGoogle Scholar
  37. 37.
    Druker BJ, Sawyers CL, Kantarjian H et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042PubMedCrossRefGoogle Scholar
  38. 38.
    Yilmaz OH, Valdez R, Theisen BK et al. (2006) Pten dependence distinguished haematopoietic stem cells from leukemia-initiating cells. Nature 441:475–482PubMedCrossRefGoogle Scholar
  39. 39.
    Zhang J, Grindley JC, Yin T et al. (2006) Pten maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441:518–522.PubMedCrossRefGoogle Scholar
  40. 40.
    Xu Q, Thompson JE, Carroll M (2005) mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 106:4261–4268.PubMedCrossRefGoogle Scholar
  41. 41.
    Owens BM, Hawley RG (2002) HOX and non-HOX homeobox genes in leukemic hematopoiesis. Stem Cells 20:364–379PubMedCrossRefGoogle Scholar
  42. 42.
    Armstrong SA, Staunton JE, Silverman LB et al. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30:41–47.PubMedCrossRefGoogle Scholar
  43. 43.
    Ayton PM, Cleary ML (2003) Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17:2298–2307.PubMedCrossRefGoogle Scholar
  44. 44.
    Scholl C, Bansal D, Dohner K et al. (2007) The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. J Clin Invest 117:1037–1048.PubMedCrossRefGoogle Scholar
  45. 45.
    Wernig M, Meissner A, Foreman R et al. (2007) In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448:318–324.PubMedCrossRefGoogle Scholar
  46. 46.
    Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676.PubMedCrossRefGoogle Scholar
  47. 47.
    Masui S, Nakatake Y, Toyooka Y et al. (2007) Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9:625–635.PubMedCrossRefGoogle Scholar
  48. 48.
    Hanna J, Markoulaki S, Schorderet P et al. (2008) Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 133:250–264.PubMedCrossRefGoogle Scholar
  49. 49.
    Gaussmann A, Wenger T, Eberle I et al. (2007) Combined effects of the two reciprocal t(411) fusion proteins MLL.AF4 and AF4.MLL confer resistance to apoptosis, cell cycling capacity and growth transformation. Oncogene 26:3352–3363.PubMedCrossRefGoogle Scholar
  50. 50.
    Wang L, O‘Leary H, Fortney J, Gibson LF (2007) Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells. Blood 110:3334–3344.PubMedCrossRefGoogle Scholar
  51. 51.
    Nichols J, Zevnik B, Anastassiadis K et al. (1998) Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95:379–391.PubMedCrossRefGoogle Scholar
  52. 52.
    Ling TY, Kuo MD, Li CL et al. (2006) Identification of pulmonary Oct-4+ stem/progenitor cells and demonstration of their susceptibility to SARS coronavirus (SARS-CoV) infection in vitro. Proc Natl Acad Sci USA 103:9530–9535.PubMedCrossRefGoogle Scholar
  53. 53.
    Chen Y, Chan VS, Zheng B et al. (2007) A novel subset of putative stem/progenitor CD34+Oct-4+ cells is the major target for SARS coronavirus in human lung. J Exp Med 204:2529–36.PubMedCrossRefGoogle Scholar
  54. 54.
    Hajdu M, Luttun A, Pelacho B et al. (2007) Transcriptional characterization of the Notch signaling pathway in rodent multipotent adult progenitor cells. Pathol Oncol Res 13:302–310.PubMedCrossRefGoogle Scholar
  55. 55.
    Lengner CJ, Camargo FD, Hochedlinger K et al. (2007) Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell 1:403–415.PubMedCrossRefGoogle Scholar
  56. 56.
    Camara-Clayette V, Le Pesteur F, Vainchenker W, Sainteny F (2006) Quantitative Oct4 overproduction in mouse embryonic stem cells results in prolonged mesoderm commitment during hematopoietic differentiation in vitro. Stem Cells 24:1937–1945.PubMedCrossRefGoogle Scholar
  57. 57.
    Kucia M, Reca R, Campbell FR et al. (2006) A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia 20:857–869.PubMedCrossRefGoogle Scholar
  58. 58.
    Keith B, Simon MC (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129:465–472.PubMedCrossRefGoogle Scholar
  59. 59.
    Babaie Y, Herwig R, Greber B et al. (2007) Analysis of Oct4-dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. Stem Cells 25:500–510.PubMedCrossRefGoogle Scholar
  60. 60.
    Hochedlinger K, Yamada Y, Beard C et al. (2005) Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121:465–477.PubMedCrossRefGoogle Scholar
  61. 61.
    Willert J, Epping M, Pollack JR et al. (2002) A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2:8–16.PubMedCrossRefGoogle Scholar
  62. 62.
    Ratke F, Clevers H (2005) Self-renewal and cancer of the gut: the two sides of a coin. Nature 307(5717):1904–1909.Google Scholar
  63. 63.
    Coluccia AM, Vacca A, Dunach M et al. (2007) Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 26:1456–1466.PubMedCrossRefGoogle Scholar
  64. 64.
    Ress A, Moelling K (2005) Bcr is a negative regulator of the Wnt signalling pathway. EMBO Rep 6:1095–1100.PubMedCrossRefGoogle Scholar
  65. 65.
    Reya T, Duncan AW, Ailles L et al. (2003) A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423:409–414.PubMedCrossRefGoogle Scholar
  66. 66.
    Scheller M, Huelsken J, Rosenbauer F et al. (2006) Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. Nat Immunol 7:1037–1047.PubMedCrossRefGoogle Scholar
  67. 67.
    Kirstetter P, Anderson K, Porse BT et al. (2006) Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol 7:1048–1056.PubMedCrossRefGoogle Scholar
  68. 68.
    Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B et al. (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 103(8):2794–2799PubMedCrossRefGoogle Scholar
  69. 69.
    Mazieres J, You L, He B, Xu Z, Lee AY, Mikami I et al. (2005) Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(119) translocation induces apoptosis. Oncogene 24:5396–5400.PubMedCrossRefGoogle Scholar
  70. 70.
    Emami KH, Nguyen C, Ma H, Kim DH et al. (2004) A small molecule inhibitor of beta-catenin/CREB-binding protein transcription. Proc Natl Acad Sci USA 101:12682–12687.PubMedCrossRefGoogle Scholar
  71. 71.
    Sukhdeo K, Mani M, Zhang Y, Dutta J et al. (2007) Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 104:7516–7521.PubMedCrossRefGoogle Scholar
  72. 72.
    Feuring-Buske M, Frankel AE, Alexander RL, et al. (2002) A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 62:1730–1736.PubMedGoogle Scholar
  73. 73.
    Strizzi L, Bianco C, Normanno N, Salomon D (2005) Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene 24:5731–5741.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  1. 1.Leukemia Research ProgramChildrens Hospital Los AngelesLos AngelesUSA

Personalised recommendations